Galera Therapeutics, Inc. (GRTX)
| Market Cap | 16.12M +761.5% |
| Revenue (ttm) | n/a |
| Net Income | 63.52M |
| EPS | 0.64 |
| Shares Out | 160.43M |
| PE Ratio | 0.16 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 204,186 |
| Open | 0.1000 |
| Previous Close | 0.1010 |
| Day's Range | 0.1000 - 0.1000 |
| 52-Week Range | 0.0151 - 0.1500 |
| Beta | 2.64 |
| RSI | 70.03 |
| Earnings Date | May 21, 2026 |
About Galera Therapeutics
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company’s lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatme... [Read more]
Financial Performance
Financial StatementsNews
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
CAMBRIDGE, Mass. and MALVERN, Pa., April 14, 2026 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibi...
Galera Therapeutics, Obsidian Therapeutics enter merger agreement
Galera Therapeutics (GRTX) and Obsidian Therapeutics entered into a definitive merger agreement to combine in an all-stock transaction. The combination will be accomplished by both companies becoming ...
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
CAMBRIDGE, Mass. & MALVERN, Pa.--(BUSINESS WIRE)--Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor through clinical...
Biossil to acquire Galera’s dismutase mimetics portfolio for up to $105M
Galera Therapeutics (GRTX) entered into an asset purchase agreement with Toronto-based biotech Biossil for the acquisition of Galera’s dismutase mimetics portfolio, including avasopasem and rucosopase...
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera's dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The agr...
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
Galera Therapeutics (GRTX) has completed the acquisition of Nova Pharmaceuticals, a privately held biotechnology company advancing a pan-NOS Inhibitor to treat patients with highly resistant forms of ...
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer.
Galera Therapeutics reports Q2 EPS (7c) vs. (48c) last year
As of June 30, 2024, Galera had cash and cash equivalents of $10.7 million. Galera expects that its existing cash and cash equivalents will enable Galera to fund its operating…
Galera Therapeutics to reduce workforce to three employees
As previously reported, the Company had engaged Stifel, Nicolaus & Company, Inc., as its financial advisor, to assist in reviewing strategic alternatives with the goal of maximizing value for its…
Galera Therapeutics announces board approval of liquidation, dissolution
Galera Therapeutics announced that its Board of Directors has approved a Plan of Liquidation and Dissolution, which provides for the dissolution of the Company under Delaware law, and plans to…
Galera Announces Board Approval of Complete Liquidation and Dissolution
MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary...
Galera Therapeutics reports Q1 EPS (8c) vs (50c) last year
“Our review of strategic options continues, as we strive to maximize value for our stockholders,” said Mel Sorensen, M.D., Galera’s President and CEO. “Potential options may include mergers, asset sal...
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics ...
Galera Therapeutics adopts limited duration stockholder rights agreement
Galera Therapeutics announced that its Board of Directors has unanimously resolved to adopt a limited duration stockholder rights agreement to protect stockholder interests. The Board resolved to adop...
Galera Adopts Limited Duration Stockholder Rights Agreement
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the p...
Galera Therapeutics reports Q4 EPS (10c) vs (58c) last year
“As a result of last year’s FDA request for a second Phase 3 trial to support the avasopasem NDA, we have implemented key measures to extend our cash runway and…
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 202...
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential stra...
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro...
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps
Galera shares tank after US FDA declines to approve inflammation disease drug
Galera Therapeutics Inc said the U.S. health regulator declined to approve its drug to treat radiotherapy-induced severe mouth inflammation in patients with advanced head and neck cancer undergoing st...
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023